This research study on the Human Papillomavirus (HPV) Associated Disorders Market published by Gravitas Market Insights is an intelligence report with thorough efforts taken to study the precise and significant information. There has been an increase in the prevalence of HPV-related diseases and the development in its treatment procedures, due to this the global Human Papillomavirus (HPV) Associated Disorders Market is anticipated to witness constant growth during the forecast period. In 2020, the global market size was estimated at USD 18.2 Billion and is anticipated to gain a CAGR of 4.8% during the forecast period. HPV is the most common viral infection which comes under one of many sexually transmitted diseases. It triggers the growth of the skin or mucous membrane i.e., warts, and there are more than 100 human papillomaviruses (HPV) varieties. Some HPVs can cause life-threatening disorders and diseases; and many forms of cancers are related to HPV infection, including cervical cancer, warts, and anal cancer among others.
The report studies several aspects of the current industry such as the market status, market size, trends of the market and the forecast. The research study also delivers brief info on the competitors and some growth opportunities along with the primary market drivers. The data is analysed by considering both, the present top players, and the forthcoming market competitors. Besides, strategies followed by the key market players have been studied well in this report. Well, explained SWOT analysis, revenue share, and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.
The Growing Burden of Cervical Cancer
Infection with human papillomavirus (HPV) is the primary cause of cervical cancer that claims the lives of 311,000 women each year, especially in low-income countries. Without changes in prevention and control, by 2035, cervical cancer deaths are forecast to rise to 416,000.
The most effective method to reduce the rapid increase of burden of cervical cancer is immunising against HPV infection, combined with proper screening and treatment. Women majorly lack access to cancer screening and treatment services in low-income countries, hence immunising girls prior to HPV exposure is extremely critical. Safe and effective HPV vaccines can prevent up to 90% of all cervical cancer cases.
Impact of COVID19 on the market:
The COVID19 pandemic crippled the global economy, it resulted in a worldwide lockdown, and this has majorly impacted numerous industries. Our industry experts are working round-the-clock to identify, accumulate and in-time deliver market analysis because of unprecedented decisions in COVID-19 repercussions on many businesses. The full version of this report will comprise the overall impact of the pandemic and predicted alteration on the outlook of the industry, by taking into account the economic, political, technological, and social parameters.
The global Human Papillomavirus (HPV) Associated Disorders Market research report provides business intelligence insights through several factors and some of the many highlights of the report are:
- Panoptic evaluation of the parent market
- Growth of significant aspects of the market
- Analysis of the market segments across industries
- Market assessment in the past, present and during the forecast years
- Strategic approach of key market players
- Productive strategies to assist companies boost their place in the market
The report speaks about the following segments in detail:
Human Papillomavirus (HPV) Associated Disorders Market Breakdown Data by Indication
- Cervical Intraepithelial Neoplasia (CIN)
- Anal Intraepithelial Neoplasia (AIN)
- Cervical Cancer
- Genital Warts
- Anal Cancer
- Other Indications
Human Papillomavirus (HPV) Associated Disorders Market Breakdown Data by Therapy
- Treatment
- Prevention
Human Papillomavirus (HPV) Associated Disorders Market Breakdown Data by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Human Papillomavirus (HPV) Associated Disorders Market Report covers the following key players:
- MERCK & CO., INC.
- F. HOFFMANN-LA ROCHE AG
- NORTHROP GRUMMAN CORPORATION
- GLAXOSMITHKLINE PLC
- Biocon Ltd.
- Eli Lilly and Company
- AstraZeneca plc
- Pfizer, Inc
- Johnson & Johnson Services, Inc.
- Novartis AG
Region-wise, the global Human Papillomavirus (HPV) Associated Disorders market is segmented into the following:
- North America (United States, Canada, Mexico)
- Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe)
- Asia Pacific (China, India, Japan, Korea, Australia, Southeast Asia, Rest of Asia Pacific)
- South America (Brazil, Argentina, Colombia, Rest of South America)
- Middle East & Africa (GCC, South Africa, Rest of Middle East & Africa)
Why do our clients trust us and why you should purchase reports from us?
- You will get a thorough understanding of the Human Papillomavirus (HPV) Associated Disorders market and its complete functioning.
- Determine the present situation of the market and future growth potential of the Human Papillomavirus (HPV) Associated Disorders market throughout the forecast period.
- The report talks about the market’s different risks and challenges in front of the market
- Strategize marketing, market-entry, market development, and other business plans by understanding factors that affect the market’s growth and the purchase decisions of the potential buyers.
- There is an in-depth analysis of different market segments like product, type, application, end-users, etc.
- The report gives you the key outcomes of the SWOT analysis of the global Human Papillomavirus (HPV) Associated Disorders Market.
This research study involves broad usage of both secondary and primary data sources. The research process involves the identification of numerous factors which affect the industry, comprising the market environment, government policy, historical data, present trends in the market, competitive landscape, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges.
Market Estimation
Top-down and bottom-up approaches are used for validating the market size for companies, regional segments along with relevant market segmentations such as product type and application.
This report includes market estimations which are based on the marketed sale price of a product. Further breakdown of product segments, particular market share are formed based on the weightage assigned to every segment, which is derived of their usage rate and average price. The entire probable factors which effect the markets and influence them in a great way are included in this research report; and have been accounted for, studied in-depth and are confirmed through primary research. These are then studies to get the final qualitative and quantitative data. Any of the factors such as the outcome of inflation, economic downfall, and any kind of policy and regulatory alterations and/or other such factors are not accounted for in the market forecast. All of this data is amalgamated and included with thorough inputs and analysis from Gravitas Market Insights is curated in this report.
Along with the previously mentioned approaches, various data triangulation methods, in order to conduct market estimations and market forecasting for the complete market segments are detailed in this report. Key Companies present in the said market are also acknowledged via in-depth secondary research and primary research.
Section 1: Executive Summary
1.1. Human Papillomavirus (HPV) Associated Disorders Market Industry 360° outline, Year 2016 – 2028
1.2. Business Model Trends
1.3. Growth Trends
1.4. End-User/Distribution Channel Trends
1.5. Regional Trends
Section 2: Market Dynamics - Human Papillomavirus (HPV) Associated Disorders Market Industry Insights
2.1. Growth Drivers
2.2. Opportunities
2.3. Industry challenges
2.4. SWOT Analysis
2.5. Porter’s Analysis
2.6. Worldwide Industry Landscape, Year 2016 – 2028
2.7. Industry Segmentation
2.8. Technology & Invention landscape
2.9. Regional Landscape
2.9.1. North America
2.9.2. Europe
2.9.3. Asia-Pacific
2.9.4. South America
2.9.5. Middle East & Africa
2.10. Competitive Environment
Section 3: Global Human Papillomavirus (HPV) Associated Disorders Market, By Indication
3.1. Segmentation Analysis, By Indication, 2016-2028
3.2. Market Share Segmentation Analysis, By Indication, 2016-2028
3.3. Cervical Intraepithelial Neoplasia (CIN)
3.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.4. Anal Intraepithelial Neoplasia (AIN)
3.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.5. Cervical Cancer
3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.6. Genital Warts
3.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.7. Anal Cancer
3.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
3.8. Other Indications
3.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
Section 4: Global Human Papillomavirus (HPV) Associated Disorders Market, By Therapy
4.1. Segmentation Analysis, By Therapy, 2016-2028
4.2. Market Share Segmentation Analysis, By Therapy, 2016-2028
4.3. Treatment
4.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
4.4. Prevention
4.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
Section 5: Global Human Papillomavirus (HPV) Associated Disorders Market, By Distribution Channel
5.1. Segmentation Analysis, By Distribution Channel, 2016-2028
5.2. Market Share Segmentation Analysis, By Distribution Channel, 2016-2028
5.3. Retail Pharmacies
5.3.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.4. Hospital Pharmacies
5.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
5.5. Online Pharmacies
5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
Section 6: Global Human Papillomavirus (HPV) Associated Disorders Market, Regional Analysis
6.1. Global Human Papillomavirus (HPV) Associated Disorders Market, Regional Analysis
6.2. North America, Country level Analysis
6.2.1. North America Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Indication, 2016 – 2028
6.2.2. North America Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Therapy, 2016 – 2028
6.2.3. North America Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Distribution Channel, 2016 – 2028
6.2.4. United States
6.2.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.2.5. Canada
6.2.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.2.6. Mexico
6.2.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3. Europe Country level Analysis
6.3.1. Europe Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Indication, 2016 – 2028
6.3.2. Europe Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Therapy, 2016 – 2028
6.3.3. Europe Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Distribution Channel, 2016 – 2028
6.3.4. UK
6.3.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.5. Germany
6.3.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.6. France
6.3.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.7. Italy
6.3.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.8. Spain
6.3.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.9. Russia
6.3.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.3.10. Rest of Europe
6.3.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4. Asia-Pacific Country level Analysis
6.4.1. Asia-Pacific Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Indication, 2016 – 2028
6.4.2. Asia-Pacific Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Therapy, 2016 – 2028
6.4.3. Asia-Pacific Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Distribution Channel, 2016 – 2028
6.4.4. China
6.4.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.5. India
6.4.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.6. Japan
6.4.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.7. Korea
6.4.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.8. Australia
6.4.8.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.9. Southeast Asia
6.4.9.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.4.10. Rest of Asia-Pacific
6.4.10.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5. South America Country level Analysis
6.5.1. South America Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Indication, 2016 – 2028
6.5.2. South America Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Therapy, 2016 – 2028
6.5.3. South America Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Distribution Channel, 2016 – 2028
6.5.4. Brazil
6.5.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5.5. Argentina
6.5.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5.6. Colombia
6.5.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.5.7. Rest of South America
6.5.7.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.6. Middle East & Africa Country level Analysis
6.6.1. MEA Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Indication, 2016 – 2028
6.6.2. MEA Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Therapy, 2016 – 2028
6.6.3. MEA Human Papillomavirus (HPV) Associated Disorders Market estimates and forecast with Growth rate analysis, By Distribution Channel, 2016 – 2028
6.6.4. GCC
6.6.4.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.6.5. South Africa
6.6.5.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
6.6.6. Rest of Middle East & Africa
6.6.6.1. Market estimates and forecast with Growth rate analysis, 2016 – 2028
Section 7: Company Profile - Human Papillomavirus (HPV) Associated Disorders Market
7.1. MERCK & CO., INC.
7.1.1. Business Overview
7.1.2. Product & Service Offering
7.1.3. Overall Revenue
7.1.4. Strategic Outlook
7.2. F. HOFFMANN-LA ROCHE AG
7.2.1. Business Overview
7.2.2. Product & Service Offering
7.2.3. Overall Revenue
7.2.4. Strategic Outlook
7.3. NORTHROP GRUMMAN CORPORATION
7.3.1. Business Overview
7.3.2. Product & Service Offering
7.3.3. Overall Revenue
7.3.4. Strategic Outlook
7.4. GLAXOSMITHKLINE PLC
7.4.1. Business Overview
7.4.2. Product & Service Offering
7.4.3. Overall Revenue
7.4.4. Strategic Outlook
7.5. Biocon Ltd.
7.5.1. Business Overview
7.5.2. Product & Service Offering
7.5.3. Overall Revenue
7.5.4. Strategic Outlook
7.6. Eli Lilly and Company
7.6.1. Business Overview
7.6.2. Product & Service Offering
7.6.3. Overall Revenue
7.6.4. Strategic Outlook
7.7. AstraZeneca plc
7.7.1. Business Overview
7.7.2. Product & Service Offering
7.7.3. Overall Revenue
7.7.4. Strategic Outlook
7.8. Pfizer, Inc.
7.8.1. Business Overview
7.8.2. Product & Service Offering
7.8.3. Overall Revenue
7.8.4. Strategic Outlook
7.9. Johnson & Johnson Services, Inc.
7.9.1. Business Overview
7.9.2. Product & Service Offering
7.9.3. Overall Revenue
7.9.4. Strategic Outlook
7.10. Novartis AG
7.10.1. Business Overview
7.10.2. Product & Service Offering
7.10.3. Overall Revenue
7.10.4. Strategic Outlook
7.11. Cytovation AS
7.11.1. Business Overview
7.11.2. Product & Service Offering
7.11.3. Overall Revenue
7.11.4. Strategic Outlook
*Market size and forecast will be provided from 2016-2028, and forecast period would be 2022-2028
*Details on financial performance and strategic moves and developments may not be captured for unlisted companies
*List of companies profiled in this TOC is tentative and may change after detailed analysis
